GE HealthCare produces much of the infrastructure required for theranostics, including cyclotrons, chemistry synthesis, pharmaceutical diagnostics, PET/CT, PET/MR, SPECT/CT, and advanced oncology and digital solutions.

BAMF Health will provide a platform designed to accelerate and scale theranostics affordably, accounting for radiopharmaceutical manufacturing, molecular imaging, molecular therapy, and a robust clinical trials program, whose operations are supported by a technology platform that is inclusive of software and AI.


The Grand Rapids cancer care provider was established specifically to scale access to molecular medicine and theranostics, and opened its theranostics center last summer, which includes Michigan’s first total-body scanner.

"Collaborating with industry complementors would facilitate knowledge sharing and standardization, yielding lower costs across the board. Empowering patients with the knowledge needed to make informed decisions about theranostics will increase acceptance and demand for these services," Dr. Anthony Chang, founder and CEO BAMF Health, told HCB News.

GE HealthCare is partnering with several companies and healthcare providers in theranostics care. It recently announced a collaboration with SOFIE Biosciences to develop investigational Gallium-68 and Fluorine-18 diagnostic radiopharmaceuticals for this type of care in clinical trials and then obtain regulatory approvals for selling them in various areas.

It also this summer partnered with teaching hospital St. Joseph’s Health Care London, in Ontario, and its research component, the Lawson Health Research Institute, to establish Canada’s first Centre of Excellence for Molecular Imaging and Theranostics (MIT), which will set the foundation for future theranostic centers in the country and foster more partnerships.

Back to HCB News

Molecular Imaging Homepage